title: Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
authors.affiliation: Astex Pharmaceuticals, 4420 Rosewood Drive, Suite 200, Pleasanton, CA 92488, USA.
authors.forename: James N
authors.initials: JN
authors.lastname: Lowder
authors.affiliation: Astex Pharmaceuticals, 4420 Rosewood Drive, Suite 200, Pleasanton, CA 92488, USA.
authors.forename: Pietro
authors.initials: P
authors.lastname: Taverna
authors.affiliation: Fels Institute, Temple University School of Medicine & Cancer Epigenetics Program, Fox Chase Cancer Center, Temple Health, 3307 North Broad Street, Room 154, Philadelphia, PA 19140, USA.
authors.forename: Jean-Pierre J
authors.initials: JP
authors.lastname: Issa
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003564:Cytidine Deaminase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000077209:Decitabine; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004355:Drug Stability; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D006207:Half-Life; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
chemical_list: D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; C580831:guadecitabine; D000077209:Decitabine; D015254:DNA Modification Methylases; D003564:Cytidine Deaminase; D001374:Azacitidine
keywords: azacitidine; decitabine; guadecitabine; hypomethylating agents